CD274 and hepatocellular carcinoma: The pairing of the anti‐PD‐L1 antibody Atezolizumab with the anti‐VEGF‐A antibody Bevacizumab has set a new benchmark for first‐line treatment, achieving a median OS duration of 19 months in patients with advanced HCC.119